Role of the Microbiome in Regulating Bone Metabolism and Susceptibility to Osteoporosis

Owen Cronin1,2 · Susan A. Lanham-New3 · Bernard M. Corfe4 · Celia L. Gregson5,6 · Andrea L. Darling3 · Kourosh R. Ahmadi3 · Philippa S. Gibson7 · Jon H. Tobias5,6 · Kate A. Ward6,9 · Maria H. Traka10 · Megan Rossi7 · Claire Williams11 · Nicholas C. Harvey8,9 · Cyrus Cooper8,9,12 · Kevin Whelan7 · André G. Uitterlinden13 · Paul W. O’Toole14 · Claes Ohlsson15 · Juliet E. Compston16 · Stuart H. Ralston1,2

Received: 4 August 2021 / Accepted: 4 October 2021 / Published online: 6 December 2021 © The Author(s) 2021

Abstract

The human microbiota functions at the interface between diet, medication-use, lifestyle, host immune development and health. It is therefore closely aligned with many of the recognised modifiable factors that influence bone mass accrual in the young, and bone maintenance and skeletal decline in older populations. While understanding of the relationship between micro-organisms and bone health is still in its infancy, two decades of broader microbiome research and discovery supports a role of the human gut microbiome in the regulation of bone metabolism and pathogenesis of osteoporosis as well as its prevention and treatment. Pre-clinical research has demonstrated biological interactions between the microbiome and bone metabolism. Furthermore, observational studies and randomized clinical trials have indicated that therapeutic manipulation of the microbiota by oral administration of probiotics may influence bone turnover and prevent bone loss in humans. In this paper, we summarize the content, discussion and conclusions of a workshop held by the Osteoporosis and Bone Research Academy of the Royal Osteoporosis Society in October, 2020. We provide a detailed review of the literature examining the relationship between the microbiota and bone health in animal models and in humans, as well as formulating the agenda for key research priorities required to advance this field. We also underscore the potential pitfalls in this research field that should be avoided and provide methodological recommendations to facilitate bridging the gap from promising concept to a potential cause and intervention target for osteoporosis.

Keywords Osteoporosis · Microbiome · Immunology · Probiotics

Introduction

This viewpoint article summarizes current knowledge in the microbiome field and identifies research priorities to advance microbiome research in osteoporosis and bone health. Most of the studies in this field have focussed on analysis of the microbiome content of faeces or stool samples which are considered to represent the gut microbiome. Therefore, within this article we will use the broad term “gut microbiome” to describe this research while acknowledging that there is actually very little information on the microbiome content in different parts of the intestine. The overall goal is to improve our current understanding of the relationship between the microbiome and bone health, and to translate this knowledge into actionable recommendations to prevent the development of osteoporosis or to find a cure for patients with this condition.

The Gut Microbiome and Osteoporosis: An Appetite for Discovery and Translation

It has been estimated that nine million fragility fractures occur worldwide each year, which are associated with significant morbidity and mortality [1–3]. The therapeutic options for osteoporosis that reduce fracture risk have expanded as anabolic agents have become available [4, 5]. Despite this, primary and secondary fracture prevention
remains sub-optimal [6]. The reasons for this are multifactorial but include fear of adverse effects of medication and poor co-ordination of healthcare systems [7–9]. A frequent question asked by patients is; “are there any supplements, changes in diet or lifestyle change that I can make instead of taking drugs?” [10].

Over the last two decades, the development and availability of high-throughput next-generation genome sequencing technologies has facilitated the characterization of the array of micro-organisms that reside within the human intestine, known as the gut microbiota. Our understanding of the collective genome of these microbes, known as the gut microbiome, is ever-expanding. It is now well-established that the composition, and in many cases, the functional potential and metabolic activity of the gut microbiome is heavily influenced by factors such as diet [11], medication use with drugs such as glucocorticoids and broad-spectrum antibiotics [12, 13], as well as frailty and ageing [14]. Co-incidentally, many of these variables also contribute to the pathogenesis of osteoporosis (Fig. 1) [15]. Whilst well-established mechanisms exist to explain how these factors affect fracture risk, it is pertinent to explore the influence that the gut microbiome may have both directly on bone architecture and metabolism, and indirectly through its interactions with ‘traditional’ risk factors for osteoporosis.

Historically, the relationship between the gut microbiota and bone health has received scant attention in the literature. However, in less than five years, mechanistic studies in animals have progressed to association studies in humans; and onwards to clinical trials of the effects of probiotics in women with reduced bone mineral density (BMD) [16–19]. The acceleration in microbiome research in bone metabolism is not unique since interest has increased exponentially across many other medical specialties. Exploring the influence of the microbiota on bone health provides a novel and exciting means of advancing our understanding of the pathogenesis of osteoporosis and potentially unearthing new preventative and therapeutic targets.

Fig. 1 Contributing factors that influence the development of the gut microbiota and the pathogenesis of osteoporosis. While many factors influencing the microbiome and development of osteoporosis overlap, the effects of others are unknown or are under active investigation
Knowledge to Date: Animal Studies

A new term of osteo-microbiology was introduced for the rapidly emerging research field of the role of the gut microbiota in bone health [20]. Much of the interest stemmed from initial findings in murine studies [21]. The available literature may be broadly compartmentalized across three categories of animal studies; Germ-free (GF) murine studies; antibiotic/probiotic/prebiotic intervention studies; and models of postmenopausal osteoporosis.

Germ-Free (GF) Murine Models

One of the earliest studies, by Sjögren et al. demonstrated that mice raised in GF environments, who therefore lack a gut microbiota, exhibited higher trabecular bone mass and reduced osteoclastic activity compared to conventionally raised mice [22]. Furthermore, repopulation of the gut of the GF mice with microbiota from the distal intestine of conventionally-raised mice led to a normalization in bone mass. This suggests that the presence of the gut microbiota is required for normal osteoclastic activity. Further studies by this group demonstrate that the ability of the gut microbiota to increase osteoclastogenic RANKL and TNF-α activity in bone is dependent on Nod-like receptors NOD1 and NOD2 in the host [23]. NOD-like receptors are pattern recognition receptors, representing a critical component of innate immunity, supporting the hypothesis that the gut microbiota may affect bone turnover in an immune-mediated manner.

Whilst an increase in bone mass in GF mice has been replicated by others [24], the degree of reduction or normalization of bone mass in GF mice following reconstitution of the intestine with micro-organisms has not been consistent across all investigations. A study by Quach et al. did not identify significant change in trabecular bone volume in GF mice reconstituted with faeces from human vegetarians and omnivores, nor with caecal microbiota from conventionally raised mice [25]. The authors of this study highlight the genetic make-up of the mouse model and selection of donor microbial communities as key considerations that may influence the outcomes on bone health following microbial colonization of GF animals.

GF mouse models have also been used to investigate the mediators of microbiota-dependent bone mass regulation. Two separate studies in GF mice have implicated the production of short chain fatty acids (SCFA) such as butyrate and acetate by the gut microbiota as an important mediator of bone formation [26, 27]. Based on their work in GF CB6F1 mice, Yan and colleagues propose that anabolic effects on bone following chronic colonization of GF mice (8 months) with a pathogen-free microbiota are possibly mediated by insulin-like growth factor 1 (IGF-1) production [27]. Additionally, antibiotic treatment of conventionally raised mice led to a reduction in circulating IGF-1 and concurrent inhibition of bone formation. Provision of SCFA to mice who received antibiotics restored IGF-1 and bone mass to levels present in mice that were not treated with antibiotics. The potential of microbial-derived SCFA, in particular butyrate, to mediate bone formation was further supported in another GF and antibiotic-treated mouse study [26]. Here, the anabolic effects of parathyroid hormone (PTH) were dependent on an intact microbiota. Strikingly, nutritional supplementation of butyrate in antibiotic-treated mice led to restoration of the ability of daily PTH injections to stimulate bone formation and increase trabecular thickness.

Antibiotic-Intervention Studies

Antibiotics are an established effector of the human gut microbiome and when not used judiciously, can have deleterious effects on host health, including life-threatening infection with Clostridioides difficile.[28, 29] The long-term sequelae of early-life consumption of antibiotics is the subject of much interest. In the preterm infant, antibiotic use can lead to reduced intestinal species diversity and richness, in addition to long-lasting carriage of multi-drug resistant organisms [30]. Association studies indicate that antibiotic use in childhood increases the risk of developing atopy and autoimmune inflammatory disorders such as juvenile idiopathic arthritis and rheumatoid arthritis in later life [31–33].

Studies in rodents have revealed that repeated depletion of the gut microbiota in early life by pulsed oral intake of broad-spectrum antibiotics can lead to increased bone mineral content and BMD [34]. The authors suggest that the increased BMD observed in mice receiving the widely used, broad-spectrum beta-lactam, amoxicillin, may be due to a greater abundance of oxalate-degradation genes present in the gut microbiome post-antibiotic treatment. A reduction in levels of oxalate, a major calcium-binding anion in the intestinal lumen, could facilitate a greater availability and absorption of calcium from the intestines, enhancing bone mineralisation. This theory was supported by the presence of lower levels of oxalate in the faecal matter of mice receiving amoxicillin.

Another potential mechanism by which alteration of the gut microbiome may affect bone health relates to the microbial synthesis and luminal availability of vitamin K (menaquinone). Warfarin, the widely used vitamin K antagonist, has long been associated with a small increase in the risk of osteoporotic fractures in adults [35, 36]. While vitamin K can affect bone quality through several mechanisms, the presence of vitamin K-dependent γ-carboxylglutamic acid residues is crucial for osteocalcin production and bone formation [37]. Using a metagenomic-based sequencing approach, Guss and colleagues demonstrated that disruption
of the gut microbiota of C57BL/6 J inbred mice by broad spectrum antibiotics (ampicillin and neomycin) led to a reduced abundance of vitamin K-producing genes within the gut microbiome (MenB, MenC, MenG). This resulted in a subsequent deterioration in bone mineral crystallinity.[38] Their work was supported by the finding of reduced availability of menaquinone within the intestine, liver and kidney of the antibiotic-treated mice. This study provides an excellent example of how metagenomic sequencing, combined with metabolite quantification in biological samples, can provide valuable insight into functional metabolic capacity and activity, allowing us to understand how the gut microbiome can affect processes relevant to bone health.

Models of Postmenopausal Osteoporosis

To investigate whether the gut microbiome plays a role in the pathogenesis of postmenopausal osteoporosis, GF mice studies have frequently been used in combination with ovariec-tomy or with oestrogen deficiency induced by gonado-trophin-releasing hormone analogues (GnRH).

One of the more striking examples of this is provided by Li et al. [24] This study demonstrated that upregulation of osteoclastogenic cytokines in the bone marrow (IL-17, TNF-α, and RANKL) and trabecular bone loss did not occur in GF mice in response to oestrogen deficiency but did occur in conventionally raised mice [24]. This was supported by two other studies in ovariec-tomized rats, where perturbation of the indigenous microbiota with doxycycline attenuated sex steroid deficiency-induced changes in bone mineral content and mechanical properties [39, 40]. Furthermore, in the study of Li and colleagues, twice-weekly probiotic supplementation of the indigenous microbiota of sex-steroid deficient mice with Lactobacillus rhamnosus provided protection against bone loss, whereas supplementation with a non-probiotic strain of Escherichia coli did not.

Lawenius and colleagues have examined the effects of a novel probiotic, pasteurized Akkermansia muciniphila, on ovariec-tomized bone loss [41]. This mucin-degrading micro-organism provides an attractive option as a next-generation probiotic [42]. It is known to improve barrier function in the gut, has led to improved metabolic status in mice and its abundance is inversely associated with obesity and associated with the degree of athletic fitness in humans [43–45]. In the ovariec-tomized mouse model, supplementation with A. muciniphila for four weeks led to reduced fat mass accumulation, mirroring previous studies. However, in comparison to mice who received sham surgery, probiotic treatment did not confer any protective benefit on bone health. Specifically, A. muciniphila reduced bone mass in gonadal-intact mice who underwent sham ovariec-tomy but did not attenuate bone loss in ovariec-tomized mice.

In summary, the data from animal studies provide evidence to support a role of the gut microbiome on the regulation of bone mass attainment and bone remodelling. The evidence also suggests that some of the effects of oestrogen deficiency on bone health are microbiota-dependent. The effects of microbiota alteration or depletion by antibiotics is less consistent and requires further study. However, caution is needed when attributing direct causation to the effects of specific microbes or microbial communities to bone formation or resorption. This is particularly true of GF animal studies, since these conditions cannot be replicated in humans and are not directly translatable [46].

Knowledge to Date: Human Studies

Human Observational Studies

Several observational studies examining the relationship between BMD and the gut microbiota have recently been published [17, 47, 48]. All of these have used 16 s ribosomal RNA amplicon sequencing to analyse the gut microbiota. The largest study, published by Das et al. [17] examined variation in the gut microbiota according to BMD measurements in 181 adults; 60 with normal BMD, 61 with osteopenia and 60 with osteoporosis. The mean age of participants was 64 years and the cohort was predominantly female. Microbial diversity in the gut had previously been shown to correlate with frailty in elderly residents of residential homes [14], but did not associate with BMD in this younger cohort of community dwellers. A large number of potential confounders were recorded and after controlling for these, five taxa remained significantly different between the normal BMD and osteopenic/osteoporotic groups.

Interestingly, a study of the EPIC cohort (European Prospective Investigation into Cancer and Nutrition) has shown an association between vegan and vegetarian diets and fracture incidence [49]. Although the researchers did not specifically interrogate the effects of these diets on the gut microbiota, this is clearly an area of research interest given the increasing popularity of vegan and plant-based diets in young, female individuals. Furthermore, in the EPIC-Norfolk cohort, observational analysis of the relationship between the Mediterranean diet and fracture incidence demonstrated that greater adherence to the diet was associated with a significant reduction in fracture risk [50]. Although, it is not possible to attribute causation to this, long-term adherence to the Mediterranean diet is known to directly impact the gut microbiota with resultant health benefits for the host [11, 51].
Interventional Studies

There have been several randomized controlled trials in humans investigating the effects of probiotic supplementation on bone health.

Nissen and colleagues performed a double-blind, placebo-controlled trial examining the effect of the probiotic *Lactobacillus reuteri* ATCC PTA 6475 on bone loss of women with reduced bone mass (mean age 76 years) [18]. This trial built upon convincing evidence from ovariec-tomized mice, where supplementation with *L. reuteri* ATCC PTA 6475 protected against bone resorption and loss associated with oestrogen deficiency [52]. Seventy women completed the study which involved taking the probiotic at a daily dose of $1 \times 10^{10}$ colony-forming units (CFU) per day or placebo. After one year, those receiving the probiotic supplement experienced a reduced loss of volumetric BMD at the tibia compared to those taking placebo (mean relative change $-0.83\%$ [95% CI $-1.47$ to $-0.19\%$], vs. $-1.85\%$ [95% CI $-2.64$ to $-1.07\%$]; intention to treat analysis). Subsequently, the same group of authors performed a metabolomic-based analysis of serum samples from participants in both treatment groups using liquid chromatography—tandem mass spectrometry to identify possible mechanisms for these effects. The authors identified 97 metabolites involved in multiple processes, including amino acid, peptide, and lipid metabolism which showed trends for differences between the treatment groups, but none remained significant after correction for multiple testing [53]. Accordingly the mechanisms by which *Lactobacillus reuteri* affects bone mass remains incompletely understood at present.

The effects of *Lactobacilli* probiotics for improvement of bone health was further studied using a combination of three *Lactobacillus* strains (*L. paracasei* DSM 13434, *L. plantarum* DSM 15312, and *L. plantarum* DSM 15313) in a multicentre, randomized, double-blind, placebo-controlled trial in Sweden [19]. This trial built on evidence from ovariec-tomized mice, where supplementation with the same mix of three *Lactobacillus* strains protected against bone loss associated with oestrogen deficiency [54]. Early postmenopausal women were randomized on a 1:1 basis to combination *Lactobacillus* probiotic at a daily dose of $1 \times 10^{10}$ CFU or placebo for 12 months. 234 randomized participants completed the study with the *Lactobacillus* probiotic recipients experiencing minimal loss in lumbar spine BMD over 12 months (mean percentage change $-0.01\%$ [95% CI $-0.50$ to $0.48\%$]), whereas those receiving placebo experienced a larger reduction in BMD ($-0.72\%$ [95% CI $-1.22$ to $-0.22\%$]).

In a further randomised trial performed by Takimoto and colleagues [55], 76 healthy postmenopausal Japanese women were allocated to receive the probiotic *Bacillus subtilis* (C-3102) or a matching placebo for a period of 24 weeks. There was a significant increase in total hip BMD of about 1.5% in the C-3102 group compared with the placebo group, but no significant difference in lumbar spine BMD. There was a trend for lower levels of the bone resorption markers urine NTX and serum TRAP 5b in the probiotic group at 12 weeks but this was not sustained at 24 weeks. The authors also noted changes in the relative abundance of various gut microbiota species in the C-3102 group compared with placebo. Consistent decreases in *Fusobacteria* species were noted at 12 and 24 weeks whereas the abundance of *Bifidobacterium* increased at 12 weeks in the C-3102 group. This led the authors to speculate that the decrease in *Fusobacteria* and increase in *Bifidobacterium* might favourably influence bone density by decreasing production of cytokines which regulate bone resorption. Nonetheless the authors also pointed out that overall, there was no significant correlation between the relative abundance of individual bacterial species and BMD or bone turnover markers in the study population.

In another study, Lambert and colleagues [56] investigated the effects of isoflavones and probiotics on bone health in a randomised placebo-controlled trial involving 85 postmenopausal women with osteopenia on DEXA with an average age of just over 60 years. The isoflavones and probiotics were delivered in the form of red clover extract (RCE) given twice daily for 12 months and the effects of this was compared with an identical placebo. The probiotic component of the active intervention comprised a heterogeneous culture of lactic acid producing bacteria. Participants in both groups were given calcium (1200 mg daily), magnesium (550 mg daily) and calcitriol (25 mcg daily) throughout the study. The RCE was found to significantly reduce bone loss at the lumbar spine, femoral neck and trochanter compared with placebo. In the RCE group, the bone resorption marker serum CTX-I was slightly but significantly reduced at 12 months whereas no significant change was detected in the placebo group. No significant change was detected in the bone formation marker P1NP during the study. Serum osteoprotegerin concentrations increased during the study to a similar extent in both groups. The authors concluded that the intervention was effective in slowing postmenopausal bone loss over a 12 month period but the study design did not allow them to determine whether it was the probiotic, the isoflavones or the combination of both interventions that was responsible for the effect observed.

Jafarnejad and colleagues [57] conducted a randomised placebo controlled trial of probiotics in 50 postmenopausal Iranian women with osteopenia for a 6-month period. The probiotic intervention consisted of a capsule containing seven different strains of probiotics (four species of *Lactobacillus*, two species of *Bifidobacterium* and one of *Streptococcus thermophilus*). The authors measured changes in spine and hip BMD as well as a large number
of biochemical markers of bone metabolism at baseline and at 6 months. No significant changes in BMD were observed in either group. There were nominally significant falls from baseline in serum TNFα, bone specific ALP, CTX and PTH in the probiotic group compared with placebo groups from baseline, analysed by ANCOVA, but no correction for multiple testing was applied. The authors concluded that probiotics may have reduced bone turnover and production of the pro-inflammatory cytokine TNFα which also acknowledging that the sample size was small and the duration of the study relatively brief.

In summary, the available evidence suggests that probiotic supplements can attenuate bone loss in postmenopausal women, although the studies investigating this have been short term and individually have had small sample sizes. Moving forward, it will be important to conduct larger scale studies to evaluate if the skeletal response differs with different types of probiotic and also to determine of the effects are sustained in the longer term. Few human studies have examined the effect of dietary manipulation of the gut microbiota on bone health. However, candidate nutrients such as fibre and isoflavones have been identified as potential effectors [56, 58].

**Vitamin D and the Microbiome**

Vitamin D receptors are highly expressed within the gastrointestinal tract, particularly in the small intestine and colon [59]. However, expression may be reduced in disorders associated with reduced gut microbiota diversity such as inflammatory bowel disease [60]. In a recent cross-sectional analysis of 567 older men, serum levels of calcitriol, the active hormone of vitamin D accounted for between 2 and 5% of the variance in the microbial diversity in the gut [61]. This investigation identified eight specific taxa, many from the phylum *Firmicutes*, that positively correlated with levels of calcitriol. Furthermore, participants with higher levels of circulating calcitriol were more likely to have a microbiota associated with SCFA production (butyrate), suggesting that the gut microbiota may influence vitamin D bioavailability.

It has been postulated that probiotics exert a role in increasing circulating 25-hydroxyvitamin D. A randomized controlled trial of 9-weeks of supplementation with *Lactobacillus reuteri* (NCIMB 30,242) in healthy participants led to a 25% increase in serum 25-hydroxyvitamin D in those receiving the supplement [62]. Conversely, a small, randomized controlled trial examining dose response of oral vitamin D supplementation in 20 adults with vitamin D deficiency demonstrated differential, dose-dependent increases in the relative abundance of *Bacteroides* after 8 weeks of supplementation [63].

The existing evidence suggests that the gut microbiome and probiotics may alter vitamin D metabolism within the gut, but research also indicates that increased oral vitamin D intake may affect the composition of the gut microbiota. Both these possibilities require further investigation given the widespread nature of vitamin D insufficiency in all age groups of the UK population.[64]

**Future Directions**

During the Royal Osteoporosis Society workshop, invited experts in the areas of osteoporosis, nutrition and microbiome research discussed the key knowledge gaps in the area of microbiome research as it applies to bone metabolism and osteoporosis. Specifically, the group considered the populations of interest, the key clinical questions to be addressed and the study designs that might be employed to advance the field (Table 1). A need for prospective, longitudinal observational studies was identified since both bone health and the gut microbiome are subject to temporal changes across the life course and the relationship between them at critical junctures of development and physiological change needs to be investigated (puberty, illness, menopause, frailty; see Fig. 2).

It is also known that, as for many other complex traits, the inter-individual variability in microbiota composition is partly under genetic control, and the first such genetic factors have now been identified by work of the MiBiogen consortium [65]. This is the first global collaboration of various microbiome research groups to establish more harmonized procedures to combine and analyse microbiome data from different sources. This genetic analysis will lead to a better understanding of which biological factors and pathways are controlling origin, maintenance and perturbations in the microbiome population. In addition, genetic factors have been identified by Genome-Wide Association Studies for many of the physiological variables associated with microbiota composition. This opens up the possibility to perform Mendelian Randomization studies to distinguish causal effects from associations arising due to confounding, and to inform intervention studies based on nutrition, lifestyle or therapeutics such as anti-, pro- or prebiotics [66–68].

There are many unknowns about the effects of therapeutically administered microbes on bone. While it is important to investigate these effects, it is also salient to understand how factors such as nutrients (for example wholegrain foods and fibre), dietary patterns (for example vegetarian, vegan and mediterranean diets), medication and antibiotic use, as well as medical co-morbidities, may predispose to osteoporosis by exerting impact on the gut microbiome. Research in the microbiome field so far suggests that ‘making a good microbiome bad’ (for example by adopting a Westernized diet) is a lot easier than ‘making a bad microbiome good.’ This underlines
Role of the Microbiome in Regulating Bone Metabolism and Susceptibility to Osteoporosis

the importance of advancing our knowledge of the impact of early life on development of the gut microbiome in relation to bone health.

**Design of Clinical Studies**

The research priorities identified for progression of microbiome-osteoporosis research highlight a clear need for large, prospective observational studies with long-term follow-up. To expedite this research, utilization of existing cohorts may provide some of the required answers but in some cases microbiome data may not have been collected. Cohorts such as UK-BIOBANK and the Avon Longitudinal Study of Parents and Children (ALSPAC) in the United Kingdom represent large, well-established longitudinal databases that could be useful. For interventional clinical trials that manipulate the microbiota with the intent of host benefit, a follow-up time of less than 6 to 9 months is unlikely to generate useful data, such is the time it takes for persistent, meaningful changes to be enacted upon the adult microbiota. In studies aiming to prevent complications of osteoporosis such as fractures it remains unclear what the best surrogate measure should be as primary outcomes in clinical trials. Regardless of the chosen primary outcome, we suggest that such studies

| Question of interest | Possible mechanism of investigation |
|----------------------|------------------------------------|
| **1** Are nutrition and lifestyle effects on the gut microbiota in early life (birth to adolescence) related to peak bone mass (PBM) attainment? | Longitudinal cohort study |
| **2** Are nutritional and lifestyle effects on the gut microbiota in early life (birth to adolescence) related to risk of osteoporosis in adulthood? | Longitudinal cohort study |
| **3** Are the effects of early-life antibiotic exposure (birth to adolescence) on the gut microbiota related to PBM accrual and/or bone mineral density in later life? | Longitudinal cohort study |
| **4** What are the effects of childhood illness on the development of a healthy gut microbiota and how does this affect PBM attainment and risk of osteoporosis in adulthood? | Case control studies, longitudinal cohort study |
| **5** Can the negative impact of inflammatory diseases in childhood such as IBD, asthma, JIA on adult bone health be attenuated by manipulating the gut microbiota through diet, and pro- or prebiotic use? | Targeted exploratory and intervention studies in patient populations |
| **6** Will recent changes in dietary habits such as vegan diets and gluten free diets in non coeliac individuals in younger generations affect future BMD and does this operate through alteration of the gut microbiota? | Case–control studies, Longitudinal cohort study |
| **7** Can BMD loss be attenuated by the use of targeted dietary modification or supplementation with pre- or probiotics during the perimenopausal time-span? | Clinical trials |
| **8** Can a patient’s gut microbiota influence the individualized response to medications such as bisphosphonates, PTH, calcium and vitamin D supplements? | Prospective observational study (1–5 year duration) |
| **9** Is the increased osteoporosis risk evident in underweight individuals mediated by the gut microbiota? | Longitudinal cohort study |
| **10** How does the gut microbiota affect the availability and absorption of calcium, vitamin D and other mineral nutrients such as magnesium from the gut lumen? | Experimental animal and human studies |
| **11** Can a specific or complex dietary modification such as an increased fibre, protein intake, Mediterranean or DASH diet, prebiotic or probiotic-use improve bone mineral density and at what stage in the life-course is the greatest benefit seen? | Clinical trials with long-term follow-up |
| **12** Can short chain fatty acid supplementation (directly or via increased non-starch polysaccharide intake) improve BMD and if so, at what stage of the life-cycle? | Clinical trials |
| **13** Is the reduction in BMD evident in the frail and elderly directly related to the concurrent decrease in gut microbial diversity that occurs in later life? | Cross-sectional, case–control studies, longitudinal cohort study |

*IBD* inflammatory bowel disease, *IBS* irritable bowel syndrome, *JIA* juvenile idiopathic arthritis, *BMD* bone mineral density, *PBM* peak bone mass, *DASH* dietary approaches to stopping hypertension
incorporate a minimum of 12-month participant follow-up as has been performed previously [19].

Many microbiome studies suffer from low statistical power, lack of replication and use of variable technologies to assess the microbiome. Studies with low sample sizes often represent pilot investigations, that under ideal circumstances may identify strong microbiome-phenotype correlations, but lack replication in independent settings or in larger cohorts. Intervventional studies often recruit several hundred participants [11]. Very large microbiome studies, such as the American Gut Project (>10,000 participants) [69], have the benefit of limiting technical variability as samples are usually treated uniformly, and the effects of confounding variables can be adjusted for in statistical models. Very large cohort studies may also facilitate the finding of ‘a needle in a hay-stack,’ increasing the probability of finding microbial effects that are not apparent amongst the noise of studies with smaller sample sizes [70]. Emphasis should be placed on replication of findings and this should be pursued through collaboration and replication cohorts, especially in the case of studies with smaller sample sizes.

An important consideration for all studies on the human gut microbiota, in particular association or interventional studies aimed at altering the characteristics of the microbiota, relates to the many confounding factors than can affect its composition and function. This highlights the importance of collecting data on key clinical variables that may directly affect the microbiota. These include recent antibiotic use, previous gastrointestinal surgery or illness, current medication use, smoking, alcohol intake, habitual intake of macro- and micro-nutrients, dietary supplementation, BMI and menopausal status. Adjustment for and consideration of these confounders underlines the importance of qualified biostatistical expertise and collection of sufficient and accurate metadata [71]. The availability of rich, linked metadata to microbiota sequences in data repositories is crucial to facilitate integrative, multi-study analysis across international groups and study population cohorts. We would encourage research groups to collect and submit detailed metadata and to make them available in a FAIR manner (Findable, Accessible, Interoperable, Re-usable).

**Technical Methodologies**

Choice of technology to assess the microbiota composition and function is another critical consideration in microbiome research. Over the last 5 years, there has been a shift from compositional microbiome analysis using quantitative PCR and 16S rRNA sequencing. While 16S sequencing is especially useful for large-scale profiling of microbiome samples because of its low cost and robustness, the desire to increase our understanding of pathophysiology, has seen a move towards shotgun metagenomic sequencing that provides information on gene content and therefore functional “potential” of the microbiome. True functional insights can only be obtained by a combination of metagenomic analysis of the gut microbiome with other ‘omic technologies such as transcriptomics, proteomics or metabolomics, in combination with intervention studies and Mendelian Randomization studies.

While it may seem obvious, it is noteworthy to highlight the importance of standardized procedures at many levels in microbiome research. This begins with faecal sample
collection and storage methods, as these processes can affect apparent microbiota composition and the ability to accurately use additional ‘omic technologies. Early consultation and collaboration with experienced biostatisticians and assuring availability of the appropriate software and bioinformatic pipelines are all essential components. For a more in-depth overview and further guidance, readers are directed to the referenced articles by Allaband et al. and Knight et al.\[72, 73\]

With respect to dietary assessment, the ideal and most accurate method for habitual dietary recording has long been debated (such as a 7-day food diary vs. semi-quantitative food frequency questionnaire). Like other recommendations in this section, the choice of dietary assessment tool depends on the hypothesis under investigation; the level of quantification required (frequency of food intake versus mass quantity of food); cost; time expended and use of the most accurate assessment tool within the context of the study design. Some research has suggested different dietary assessment methods capture distinct areas of diet-microbiome interaction, potentially arguing against a reliance on a single dietary tool \[74\]. The introduction of app- and web-based methods of dietary assessment, as well as emerging innovations in food image recognition and wearable technologies, promises to reduce participant burden and facilitate richer and more accurate dietary assessment. Depending on the research question at hand, it may be appropriate to consider methods for adjusting for total energy intake and energy under/over-reporting.

Concluding Remarks

Understanding of how food and nutrition affect life processes is fundamental to improving health and preventing disease. With an increasing societal awareness of the gut microbiota and the continued emphasis on the impact of food and lifestyle on health, the complex interplay between nutrition, the gut microbiome and bone health is of interest to many. Methods of analysing the gut microbiome have advanced and are now well-positioned for us to investigate the mechanisms by which modern lifestyle, diet and illness exert their effects on bone health via the gut microbiome. Microbiome research offers exciting prospects for patients with osteoporosis. We believe the next decade will provide significant progress in this new field of osteo-microbiology.

Acknowledgements The workshop was supported by the Royal Osteoporosis Society’s (ROS). The authors would like to thank Dr. Kaumal Baig Mirza who assisted with drawing of the illustrations.

Author Contributions OC, SLN, and SHR conceived the idea and structure of the manuscript. OC researched the literature and wrote the manuscript with contributions from SHR, SLN, PWOT and AU. All authors attended the Osteoporosis and Bone Research Academy workshop and contributed to the discussions and debate on the topic. All authors had the opportunity to review and edit the manuscript before its completion.

Declarations

Conflict of interest Stuart H. Ralston reports non-personal fees from UCB, Pfizer, Abbvie, Cellgene, Kyowa-Kirin, Alexion, Amgen, Cellgene, Bristol Myers Squibb, Janssen-Cilag, Novartis, Eli Lilly, Thornton & Ross, Sanofi-Genzyme, Roche and Sandoz and grants from Kyowa Kirin and Astra Zeneca, outside the submitted work. NCH reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Consilient Healthcare, Kyowa Kirin and Internis Pharma, outside the submitted work. Cyrus Cooper reports consultancy, lecture fees and honoraria from AMGEN, GSK, Alliance for Better Bone Health, MSD, Eli Lilly, Pfizer, Novartis, Servier, Medtronic and Roche outside the scope of the submitted work. Kate A. Ward reports honoraria from Abbot Nutrition, Pfizer Healthcare outside the submitted work. Juliet E. Compston reports honoraria from Amgen and UCB outside the scope of the submitted work. CO is inventor of a patent concerning the use of probiotic strains for use in treatment or prevention of osteoporosis (EPA EP2981274A4). Owen Cronin, Susan A. Lanham-New, Bernard M. Corfe, Celia L. Gregson, Andrea L. Darling, Kourosh R. Ahmadi, Philippa S. Gibson, Jon H. Tobias, Maria H. Traka, Megan Rossi, Claire Williams, Nicholas C. Harvey, Kevin Whelan, André G. Uitterlinden, and Paul W. O’Toole have no conflicts of interest to declare.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Morley JE (2017) The new geriatric giants. Clin Geriatr Med 33:xi–xii
2. Clynes MA, Gregson CL, Bruyère O, Cooper C, Dennison EM (2020) Osteosarcopenia: where osteoporosis and sarcopenia collide. Rheumatology (Oxford) 60:529–537
3. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733
4. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427

5. Khosla S, Hofbauer LC (2017) Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 5:898–907

6. Khosla S, Shane E (2016) A crisis in the treatment of osteoporosis. J Bone Miner Res 31:1485–1487

7. Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis. J Bone Miner Res 30:2179–2187

8. Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahleiter-Plammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Mörlicke R, López-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240

9. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexanderson P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722–733

10. Raybould G, Babatunde O, Evans AL, Jordan JL, Paskins Z (2018) Expressed information needs of patients with osteoporosis and/or fragility fractures: a systematic review. Arch Osteoporos 13:55

11. Ghosh TS, Rampelli S, Jeffery IB, Santoro A, Neto M, Capri KL, Stanton C, Marchesi JR, Fitzgerald AP, Shanahan F, Hill C, De Vos WM, Fairweather-Tait S, Cassidy A, Brigidi P, Franceschi E, Hermes GDA, Elodie C, Meunier N, Brugere CM, Pujos-Masclet E, van den Bogert H, Belaich E, Berendsen AM, De Groot L, Feskins EJM, Kaluza J, Korn M, Oliva-Hemker M, Rosh J, Otley A, Boyle B, Mack D, Alexander K, Abubucker S, Zhou Y, Ruiz VE, Mitreva M, Alekseyenko AV, Teitler I, Chung J, Sohn J, Barber CM, Goldfarb DS, Raju K, Darby TM, Weitzmann MN, Mulle JG, Gewirtz AT, Jones RM, Pacifici R (2016) Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest 126:2049–2063

12. O’Sullivan O, Coakley M, Lakshminarayanan B, Conde S, Claesson MJ, Cusack S, Fitzgerald GF, Deane J, O’Connor M, Harnedy N, Cusack S, Harris HM, Francoza EA, Thomas S, Gotman NM, Rufo P, Baker SS, Sauer C, Markowitz J, Pfefferkorn M, Oliva-Hemker M, Rosh J, Otley A, Boyle B, Mack D, Baldassano R, Kellj D, LeLeiko N, Heyman M, Griffiths A, Patel AS, Noe J, Kugathasan S, Walters T, Huttenhower C, Hyams J, Xavier RJ (2018) Compositional and temporal changes in the gut microbiota of pediatric ulcerative colitis patients are linked to disease course. Cell Host Microbe 24:600-610.e604

13. Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, Harris HM, Coakley M, Lakshminarayanan B, O’Sullivan O, Fitzgerald GF, Deane J, O’Connor M, Harnedy N, O’Connor K, Mahony D, van Sinderen D, Wallace M, Brennan L, Stanton C, Marchesi JR, Fitzgerald AP, Shanahan F, Hill C, Ross RP, O’Toole PW (2012) Gut microbiota composition correlates with diet and health in the elderly. Nature 488:178–184

14. Hendrickx G, Boudin E, Van Hul W (2015) A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat Rev Rheumatol 11:462–474

15. Ibáñez L, Rouleau M, Wakkach A, Blin-Wakkach C (2019) Gut microbiome and bone. Joint Bone Spine 86:43–47

16. Das M, Cronin O, Keohane DM, Cormac EM, Nugent H, Nugent M, Molloy C, O’Toole PW, Shanahan F, Molloy MG, Jeffery IB (2019) Gut microbiota alterations associated with reduced bone mineral density in older adults. Rheumatology (Oxford) 58:2295–2304

17. Nilsson AG, Sundh D, Backhed F, Lorentzon M (2018) Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial. J Intern Med 284:307–317

18. Jansson P-A, Curicai D, Lazuor Ahren H, Hansson F, Martinsson Niskanen T, Sjögren K, Ohlsson C (2019) Probiotic treatment using a mix of three Lactobacillus strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet Rheumatol 1:e154–e162

19. Ohlsson C, Sjögren K (2015) Effects of the gut microbiota on bone mass. Trends Endocrinol Metab 26:69–74

20. Ohlsson C, Sjögren K (2018) Osteomicrobiomes: a new cross-disciplinary research field. Calcif Tissue Int 102:426–432

21. Sjögren K, Engdahl C, Henning P, Lerner UH, Tremaroli V, Lagerquist MK, Bäckhed F, Ohlsson C (2012) The gut microbiota regulates bone mass in mice. J Bone Miner Res 27:1357–1367

22. Ohlsson C, Nigro G, Boneca IG, Bäckhed F, Sansonetti P, Sjögren K (2017) Regulation of bone mass by the gut microbiota is dependent on NOD1 and NOD2 signaling. Cell Immunol 317:55–58

23. Li JY, Chassaing B, Tyagi AM, Vaccaro C, Luo T, Adams J, Darby TM, Weitzmann MN, Mulle JG, Gewirtz AT, Jones RM, Pacifici R (2016) Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest 126:2049–2063

24. Quach D, Collins F, Parmeleswaran N, McCabe L, Britton RA (2018) Microbiota reconstitution does not cause bone loss in germ-free mice. mSphere. https://doi.org/10.1128/mSphere.00545-17

25. Li JY, Yu M, Pal S, Tyagi AM, Dar H, Adams J, Weitzmann MN, Jones RM, Pacifici R (2020) Parathyroid hormone-dependent bone formation requires butyrate production by intestinal microbiota. J Clin Invest 130:1767–1781

26. Ohlsson C, Sjögren K (2015) Effects of the gut microbiota on bone mass. Trends Endocrinol Metab 26:69–74

27. Yan J, Herzog JW, Tsang K, Brennan CA, Bower MA, Garrett KS, Sjögren K, Ohlsson C (2019) Probiotic treatment using a mix of three Lactobacillus strains for lumbar spine bone density: a randomized, placebo-controlled, double-blind, clinical trial. J Intern Med 284:307–317

28. Sjögren K, Engdahl C, Henning P, Lerner UH, Tremaroli V, Lagerquist MK, Bäckhed F, Ohlsson C (2012) The gut microbiota regulates bone mass in mice. J Bone Miner Res 27:1357–1367

29. Ohlsson C, Sjögren K (2018) Osteomicrobiomes: a new cross-disciplinary research field. Calcif Tissue Int 102:426–432

30. Horton DB, Scott FI, Haynes K, Putt ME, Rose CD, Lewis JD, Horton DB, Scott FI, Haynes K, Putt ME, Rose CD, Lewis JD, Schirmer M, Denson L, Vlamakis H, Franzosa EA, Thomas S, Dicks LMT, Mikkelsen LS, Brandsborg E, Marcotte H (2019) Metagenomic signatures of early-life hospitalization and antibiotic exposure in children with the difficult “Kloster” fuelled by antibiotics. Curr Microbiol 76:774–782

31. Horton DB, Scott FI, Haynes K, Putt ME, Rose CD, Lewis JD, Schirmer M, Denson L, Vlamakis H, Franzosa EA, Thomas S, Dicks LMT, Mikkelsen LS, Brandsborg E, Marcotte H (2019) Metagenomic signatures of early-life hospitalization and antibiotic exposure in children with the difficult “Kloster” fuelled by antibiotics. Curr Microbiol 76:774–782

32. Blaser MJ (2016) Antibiotic use and its consequences for the normal microbiome. Science 352:544–545

33. Sultan AA, Mallen C, Muller S, Hider S, Scott I, Helliwell T, Hall LI (2019) Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study. BMC Med 17:154

34. Noble YR, Cox LM, Kirigin FJ, Bokulich NA, Yamanishi S, Teitler I, Chung J, Sohn J, Barber CM, Goldfarb DS, Raju K, Abubucker S, Zhou Y, Ruiz VE, Li H, Mitreva M, Alekseyenko AV, Weinstock GM, Sodergren E, Blaser MJ (2015) Metabolic and metagenomic outcomes from early-life pulse antibiotic treatment. Nat Commun 6:7486

 Springer
Role of the Microbiome in Regulating Bone Metabolism and Susceptibility to Osteoporosis

35. Caraballo PJ, Heit JA, Atkinson EJ, Silverstein MD, O’Fallon WM, Castro MR, Melton LJ 3rd (1999) Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 159:1750–1756

36. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 166:241–246

37. Gundberg CM, Lian JB, Booth SL (2012) Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr 3:149–157

38. Guss JD, Taylor E, Rouse Z, Roubert S, Higgins CH, Thomas CJ, Baker SP, Vashishth D, Donnelly E, Shea MK, Booth SL, Bicalho RC, Hernandez CJ (2019) The microbial metagenome and bone tissue composition in mice with microbiome-induced reductions in bone strength. Bone 127:146–154

39. Pytlík M, Folwarczna J, Janiec W (2004) Effects of doxycycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia. Calcif Tissue Int 75:225–230

40. Folwarczna J, Pytlík M, Janiec W (2003) Effects of doxycycline on development of changes in histomorphometric parameters of bones induced by bilateral ovariectomy in rats. Pol J Pharmacol 55:433–441

41. Lawenius L, Scheffler JM, Gustafsson KL, Henning P, Nilsson KH, Colliden H, Islander U, Plovier H, Cani PD, de Vos WM, Ohlsson C, Sjogren K (2020) Pasteurized Akkermansia muciniphila protects from fat mass gain but not from bone loss. Am J Physiol Endocrinol Metab 318:E480–E491

42. O’Toole PW, Marchesi JR, Hill C (2017) Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol 2:17057

43. Arch Intern Med 166:241–246

44. Karlsson CL, Onnerfält J, Xu J, Molin G, Ahrné S, Thorngren-Kj绣in WM, Cani PD (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 110:9066–9071

45. Lawenius L, Scheffler JM, Gustafsson KL, Henning P, Nilsson KH, Colliden H, Islander U, Plovier H, Cani PD, de Vos WM, Ohlsson C, Sjogren K (2020) Pasteurized Akkermansia muciniphila protects from fat mass gain but not from bone loss. Am J Physiol Endocrinol Metab 318:E480–E491

46. Everard A, Belzer C, Geurts L, O’Toole PW, Marchesi JR, Hill C (2017) Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol 2:17057

47. Li C, Huang Q, Yang R, Dai Y, Zeng Y, Tao L, Li X, Zeng J, Shah SA, Fornage M, Szopinska-Tokov J, Wallen ZD, Borisevich A, Agreus L, Andreasson A, Bang C, Bedrani L, Bell JT, Bisgaard M, Christensen LP, Jeppesen PB (2017) Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic Japanese women: a randomized, placebo-controlled, double-blind clinical trial. Biosci Microbiota Food Health 37:87–96

48. Lambert MNT, Thybo CB, Lykkeboe S, Rasmussen LM, Frette HH, Moverare-Skrtic S, Islander U, Sjogren K (2014) Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS ONE 9:e92368

49. Tong TYN, Appleby PN, Armstrong MEG, Fensom GK, Knupfer EC, Chen D, Sun J (2015) Vitamin D receptor pathway is required for dietary extremes impact on gut microbial diversity. Gut 64:1913–1920

50. Wallace TC, Marzorati M, Spence L, Weaver CM, Williamson PS (2017) New Frontiers in fibers: innovative and emerging research on the gut microbiome and bone health. J Am Coll Nutr 36:497–506

51. Barbhuiya A, Fernández-Barral A, Ferrer-Mayorga G, Costales-Carrera A, Larriba MJ, Muñoz A (2017) The endocrine vitamin D system in the gut. Mol Cell Endocrinol 453:79–87

52. Britton RA, Irwin R, Quach D, Schafer L, Zhang J, Lee T, Par meswaran N, McCabe LR (2014) Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. J Cell Physiol 229:1822–1830

53. Li P, Sandh D, Ji B, Lappa D, Ye L, Nielsen J, Lorentzon M (2021) Metabolic alterations in older women with low bone mineral density supplemented with Lactobacillus reuteri. JMBR Plus 5:e10478

54. Ohlsson C, Engdahl C, Fak F, Andersson A, Windahl SH, Farman HH, Moverare-Skrtic S, Islander U, Sjogren K (2014) Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS ONE 9:e92368

55. Takimoto T, Hatanaka M, Hoshino T, Takara T, Tanaka K, Shimizu A, Morita H, Nakamura T (2018) Effect of Bacillus subtilis C-3102 on bone mineral density in healthy postmenopausal Japanese women: a randomized, placebo-controlled, double-blind clinical trial. Biosci Microbiota Food Health 37:87–96

56. Lamberti MNT, Thybo CB, Lykkeboe S, Rasmussen LM, Frette HH, Moverare-Skrtic S, Islander U, Sjogren K (2014) Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS ONE 9:e92368

57. Jafarnejad S, Djafarian K, Fazeli MR, Yekaninejad MS, Rostamian A, Keshavarz SA (2017) Effects of a multispecies probiotic supplement on bone health in postmenopausal osteopenic women: a randomized, double-blind, controlled trial. J Am Coll Nutr 36:497–506

58. Wallace TC, Marzorati M, Spence L, Weaver CM, Williamson PS (2017) New Frontiers in fibers: innovative and emerging research on the gut microbiome and bone health. J Am Coll Nutr 36:218–222

59. Barbhuiya A, Fernández-Barral A, Ferrer-Mayorga G, Costales-Carrera A, Larriba MJ, Muñoz A (2017) The endocrine vitamin D system in the gut. Mol Cell Endocrinol 453:79–87

60. Wu S, Yoon S, Zhang YG, Lu R, Xia Y, Wan J, Petroff EO, Cloud EC, Chen D, Sun J (2015) Vitamin D receptor pathway is required for probiotic protection in colitis. Am J Physiol Gastrointest Liver Physiol 309:G341–G349

61. Thomas RL, Jiang L, Adams JS, Xu ZZ, Shen J, Janssen S, Ackermann G, Vanderschueren D, Pauwels S, Knight R, Orwoll ES, Kado DM (2020) Vitamin D metabolites and the gut microbiome in older men. Nat Commun 11:9071

62. Britton RA, Irwin R, Quach D, Schafer L, Zhang J, Lee T, Par meswaran N, McCabe LR (2014) Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. J Cell Physiol 229:1822–1830

63. Ohlsson C, Engdahl C, Fak F, Andersson A, Windahl SH, Farman HH, Moverare-Skrtic S, Islander U, Sjogren K (2014) Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS ONE 9:e92368

64. Tong TYN, Appleby PN, Armstrong MEG, Fensom GK, Knupfer EC, Chen D, Sun J (2015) Vitamin D receptor pathway is required for dietary extremes impact on gut microbial diversity. Gut 64:1913–1920

65. Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjahzadeh D, Wang J, Demirkan A, Le Roy CI, Raygoza Garay JA, Fennicum CT, Liu X, Zhnarkova DV, Bonder MJ, Hansen TH, Frost F, Rühlemann MC, Turpin W, Moon JY, Kim HN, Lüll K, Barkan E, Shah SA, Fornage M, Szopinska-Tokov J, Wallen ZD, Borisevich A, Agreus L, Andreasson A, Bang C, Bedrani L, Bell JT, Bisgaard M, Christensen LP, Jeppesen PB (2017) Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic Japanese women: a randomized, placebo-controlled, double-blind clinical trial. Biosci Microbiota Food Health 37:87–96

66. Lamberti MNT, Thybo CB, Lykkeboe S, Rasmussen LM, Frette HH, Moverare-Skrtic S, Islander U, Sjogren K (2014) Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS ONE 9:e92368

67. Jafarnejad S, Djafarian K, Fazeli MR, Yekaninejad MS, Rostamian A, Keshavarz SA (2017) Effects of a multispecies probiotic supplement on bone health in postmenopausal osteopenic women: a randomized, double-blind, controlled trial. J Am Coll Nutr 36:497–506

68. Wallace TC, Marzorati M, Spence L, Weaver CM, Williamson PS (2017) New Frontiers in fibers: innovative and emerging research on the gut microbiome and bone health. J Am Coll Nutr 36:218–222

69. Barbhuiya A, Fernández-Barral A, Ferrer-Mayorga G, Costales-Carrera A, Larriba MJ, Muñoz A (2017) The endocrine vitamin D system in the gut. Mol Cell Endocrinol 453:79–87
